Vontier Corporation VNT Stock Consolidating at 2799 Next Move Ahead 20260518 NextEra Energy Reportedly in Talks to Acquire Dominion Energy Is Liberty FWONA Still a Buy After 074 Rally 20260514 Exelixis EXEL Delivers Q1 2026 Beat EPS 079 vs 072 Expected AI Reshapes Labor Market BlueCollar Skills in Demand as WhiteCollar Hiring Slows Novartis Lifts Annual Sales and Profit Outlook Jim Cramer Suggests Potential Buying Opportunity in VF Corporation CapitaLand Unveils 14 Billion Life Sciences Hub Geneo at Science Park SupplySide Pressures and Weather Volatility Introduce Uncertainty into Indias Macroeconomic Outlook Indian Government Plans Overhaul of Tax Administration for Smooth GST Rollout LUMN Q1 2026 Earnings Significant EPS Miss Reflects Ongoing Transformation Challenges SnapOn Q1 2026 Earnings EPS Falls Short of Expectations Shares Edge Higher Fate Therapeutics Q1 2026 Earnings EPS Beat Drives Stock Uptick Amid Continued Pipeline Progress iRhythm Q1 2026 Earnings Significant EPS Beat Amid Revenue Uncertainty VOXR Q1 2026 Earnings EPS Surges 733 Above Estimates Stock Declines 149 Intuit INTU Q1 2026 Earnings Slight EPS Miss Masks Solid Underlying Trends Mercer International MERC Bounces From Support Tests Key Resistance at 107 Bain Capital Specialty Finance BCSF Shares Slip 08 Amid NearTerm Resistance Test Range Resources RRC Holds Steady Near 41 as Energy Sector Faces Mixed Signals Aspen Aerogels ASPN Edges Higher as Key Support Holds Steady ACP Edges Higher in LowVolume Trading Consolidates Near Resistance PTN Q1 2026 Earnings EPS Beats Estimates by Wide Margin as Loss Narrows Stock Advances NVST Q1 2026 Earnings EPS Beat of 129 Fails to Lift Stock HWM Q1 2026 Earnings EPS Surges Past Estimates Driven by Aerospace Demand FMAO Q1 2026 Earnings EPS Surpasses Estimates by 38 Amid Steady Operations RRX Q1 2026 Earnings EPS Beats Estimates as Margins Improve Stock Slides Aequs Reports 33 Revenue Growth in FY26 but Losses Widen Amid Consumer Electronics Expansion DCOMP Q1 2026 Earnings Preferred Dividend Coverage Slightly Below Expectations Artiva Biotherapeutics Holds Steady with Slight Gain Support at 75 in Focus ARTV